Shield Therapeutics (FRA:1JS) Additional Paid-In Capital: €177.61 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Shield Therapeutics Additional Paid-In Capital?

Shield Therapeutics FRA:1JS -3.06% Additional Paid-In Capital is €177.61 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.


Shield Therapeutics's quarterly additional paid-in capital declined from Jun. 2025 (€176.16 Mil) to Dec. 2025 (€174.74 Mil) but then increased from Dec. 2025 (€174.74 Mil) to Jun. 2026 (€177.61 Mil).

Shield Therapeutics's annual additional paid-in capital increased from Dec. 2023 (€182.26 Mil) to Dec. 2024 (€194.05 Mil) but then declined from Dec. 2024 (€194.05 Mil) to Dec. 2025 (€174.74 Mil).

Shield Therapeutics Additional Paid-In Capital Related Terms

Shield Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Additional Paid-In Capital Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 148.17 159.99 182.26 194.05 174.74

Shield Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 184.65 194.05 176.16 174.74 177.61

Shield Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of €177.61 Mil mean?
Shield Therapeutics (FRA:1JS) has a Additional Paid-In Capital of €177.61 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Additional Paid-In Capital too high?
Shield Therapeutics' current Additional Paid-In Capital is €177.61 Mil.
How does Shield Therapeutics' Additional Paid-In Capital compare to ZTS and UTHR?
Shield Therapeutics' Additional Paid-In Capital of €177.61 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Additional Paid-In Capital is €177.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.09, compared to a current price of €0.05 — trading 47.2% below its estimated fair value. The current Additional Paid-In Capital is €177.61 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current Additional Paid-In Capital is €177.61 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.